Cerebral Palsy Market Size

Global Cerebral Palsy Market Overview

Cerebral Palsy Market Size was valued at USD 2.6 billion in 2022. The Cerebral Palsy market industry is projected to grow from USD 2.68 Billion in 2023 to USD 3.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.2% during the forecast period (2023 - 2032). The rising burden of the Palsy, investment growth, technological progress, and government initiatives are the key market drivers driving the market.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Cerebral Palsy Market Trends

• Increasing prevalence of Cerebral Palsy, increasing investment, advancements in technology, and government efforts will boost market growth

The market's revenue growth is driven by an increase in government financing and significant market participants' investments. For instance, Access Earth began its first public investment campaign on November 4, 2021, with the aid of Spark Crowdfunding. Over 7,000 individual investors have unique commission-free access to investment possibilities in startup companies thanks to the Spark Crowdfunding platform. In 2021, Spark investors spent more than $6 million on cutting-edge, high-growth startup businesses. Additionally, the most recent round of awards from the Foundation for Physical Therapy Research has helped to finance research on conditions including cerebral Palsy and muscular dystrophy. Six awards totaling USD 360,000 were given out on January 10, 2022, to research projects that describe the value of physical therapy services for patients, providers and payers; these funds include those that develop novel therapies, show the effectiveness of current treatments, and define the value of existing treatments. Thus, this factor is driving the market CAGR.

Rapid clinical trials due to expanding research and development (R&D) activities are anticipated to fuel the cerebral Palsy industry. Nine hundred-one studies of C.P. are presently being conducted through different active clinical tests and trials, according to the clinicaltrials.gov website. To confirm compliance with ClinicalTrials.gov guidelines, FDA requires applicants to complete and submit Form FDA 3674 with certain human medicine, biological product, and device applications and submissions.

Figure 1 Total number of clinical trials by phase for Cerebral Palsy

Source Secondary and Primary Research, MRFR Database and Analyst Review

Additional factors boosting the growth of the C.P. treatment market include increasing research activity and improvements in diagnostic therapy. The health of children and their families depends on early C.P. diagnosis. Additionally, scientists are doing a lot of effort to lower illness frequency ly. Additionally, they are investigating stem cells, which have demonstrated promise as a therapy for C.P. and other Central Nervous System (CNS) illnesses. The market is expanding due to more Research & Development (R&D) studies being conducted to treat this condition.

However, several typical adverse effects of C.P. medications, including weakness, tiredness, hypotension, and dizziness, as well as the availability of other effective treatment options, are anticipated to restrain the worldwide market for C.P. therapy throughout the forecast period. Given that some of the pharmaceuticals used to treat C.P. are quite potent, some doctors prefer not to prescribe particular medications to children owing to the possible influence on the child's growth and development. Expensive C.P. medications further hamper the expansion of the cerebral Palsy industry. Thus, it is anticipated that this aspect will accelerate Cerebral Palsy market revenue ly.

Cerebral Palsy Market Segment Insights

Cerebral Palsy Type Insights

The Cerebral Palsy market segmentation, based on type, includes Spastic Cerebral Palsy, Dyskinetic Cerebral Palsy, Hypotonic Cerebral Palsy, Ataxic Cerebral Palsy, Other. The Spastic Cerebral Palsy segment held the majority share in 2022 in the Cerebral Palsy market data. A developmental illness known as spastic cerebral Palsy is brought on by brain injury that occurs before birth, during delivery, or in the first few years of life. Spastic cerebral Palsy is the most prevalent kind of cerebral Palsy, accounting for 70% to 80% of all cases.

Cerebral Palsy Treatment Insights

The Cerebral Palsy market segmentation, based on Treatment, includes Therapy, Medication, and Others. The medicine part is divided into many medications, including anticholinergics, anticonvulsants, antispasmodics, and others. The anticonvulsants segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Several popular drugs, including anticonvulsants, antidepressants, anti-inflammatories, muscle relaxants, benzodiazepines, baclofen, and stool softeners, are considerably fueling this segment's market expansion. Anticonvulsant drugs, including Keppra, frequently treat C.P. children's seizure activity.

Figure 2 Cerebral Palsy Market, by Treatment, 2022 & 2030 (USD billion)

Source Secondary and Primary Research, MRFR Database and Analyst Review

Cerebral Palsy Diagnosis Insights

Based on Diagnosis, the Cerebral Palsy market segmentation includes Imaging Tests, Others. The imaging segment dominated the Cerebral Palsy market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The imaging tests segment is further divided into the following sub-segments cranial ultrasound, magnetic resonance imaging (MRI), computed tomography (C.T.), and electroencephalogram (EEG). The portion for laboratory testing is further broken down into tests for blood, urine, skin, genetic/metabolic factors, and others.

Cerebral Palsy Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Cerebral Palsy market accounted for USD 1.19 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. Due to strict government rules and restrictions and a more developed healthcare system, the U.S. accounted for a considerable rise in the market for C.P. treatments. The existence of several businesses and C.P. treatment-related R&D initiatives also contribute to the expansion of the market in this area. For instance, on November 16, 2021, Delpor, a biopharmaceutical company that leverages cutting-edge technology to produce once-yearly medicines for chronic illnesses, received a USD 2.5 million NIH funding award for the firm's tizanidine implant product (DLP-208) for moderate-severe spasticity. The Cerebral Palsy Guideline estimates that 764,000 Americans, both adults and children, have at least one cerebral Palsy symptom. About 10,000 infants are born with cerebral Palsy each year.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 CEREBRAL PALSY MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Due to the rising frequency of C.P. among youngsters, the Asia Pacific Cerebral Palsy market is anticipated to have considerable revenue growth throughout the projected period. For instance, 34,000 individuals in Australia have Cerebral Palsy, and about 700 new instances are identified annually, according to a study from the Cerebral Palsy Alliance released on June 15, 2022. Due to a growth in the number of efforts and investments in overall R&D of C.P. treatment, nations like China and India are predicted to expand at a rapid CAGR in the Asia Pacific region. Further, the China Cerebral Palsy market held the largest market share, and the India Cerebral Palsy market was the fastest-growing market in the region.

The Europe Cerebral Palsy market is anticipated to see consistent revenue growth throughout the projection period. Several regulatory approvals and collaborations between significant market players drive revenue in this area. For instance, the Food and Drug Administration (FDA) has licensed iBotox (onabotulinumtoxinA; Allergan) for treating spasticity in children older than two years, including those with lower limb stiffness brought on by cerebral Palsy. Additionally, on December 17, 2022, Proveca Ltd. and Cerebral Palsy Sport penned a sponsorship deal. This agreement also calls for several cooperative activities; the first is a webinar featuring Tully Kearney, who won the women's S5 100m Freestyle gold medal at the 2020 Tokyo Paralympics. Further, the German Cerebral Palsy market held the largest market share, and the UK Cerebral Palsy market was the fastest-growing market in the European region.

Cerebral Palsy Key Market Players & Competitive Insights

Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for cervical fusion. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their presence. Cerebral Palsy industry competitors must provide affordable products to grow and remain in a market that is becoming increasingly competitive.

Manufacturing locally to cut operational costs is one of the main business tactics used by the Cerebral Palsy industry to serve customers and increase the market sector. The Cerebral Palsy industry has recently given medicine some of the most important advantages. The Cerebral Palsy market major player such as Allergen Plc, Cellular Biomedicine Group, Merck & Co., Pfizer, GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Medtronic, and others are working on expanding the market demand by investing in research and development activities.

Several patents about QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets for oral administration were upheld by the United States District Court for the District of New Jersey on August 22, 2022, according to Tris Pharma, Inc. ('Tris'), a fully integrated pharmaceutical company with a diverse portfolio of CNS products. The ruling states that the claimed Tris patents would be violated by the proposed generic methylphenidate product from Teva Pharmaceuticals USA, Inc., as described in its Abbreviated New Drug Application (ANDA).

The Japanese division of Control Bionics inked a deal with Double Research and Development Co., Ltd. for exclusive distribution to launch full-scale operations and more effectively use technology to address the communication difficulties faced by severely disabled persons in Japan. Control Bionics has been working with users with severe impairments, such as cerebral Palsy (C.P.) and others.

Key Companies in the Cerebral Palsy market include

• Allergen Plc


• Cellular Biomedicine Group


• Merck & Co.


• Pfizer


• GlaxoSmithKline Plc


• Abbott Laboratories


• Acorda Therapeutics


• Medtronic

Cerebral Palsy Industry Developments

March 2022 The Cerebral Palsy Research Program Act, which would establish a cerebral Palsy research program inside the Centers for Disease Control and Prevention (CDC) and offer the first-ever dedicated source of federal money for cerebral Palsy research, was sponsored by Congressman Steve Cohen with cosponsors from both parties, Congressmen Brian Fitzpatrick and Emanuel Cleaver.

February 2022 A significant new relationship between the Cerebral Palsy Alliance Research Foundation (CPA) and Hearts & Minds Investments Limited has been formed to promote creative research that aims to transform neonatal intensive care ly. To lessen the prevalence and severity of cerebral Palsy and other permanent problems in children, it will help Australia's top neonatologists and bioengineers in their work.

Cerebral Palsy Market Segmentation

Cerebral Palsy Type Outlook

• Spastic Cerebral Palsy


• Dyskinetic Cerebral Palsy


• Hypotonic Cerebral Palsy


• Ataxic Cerebral Palsy


• Other

Cerebral Palsy Diagnosis Outlook

• Imaging Tests


• Others

Cerebral Palsy Treatment Outlook

• Therapy


• Medication


• Other

Cerebral Palsy Regional Outlook

North America

• US


• Canada

Europe

• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe

Asia-Pacific

• China


• Japan


• India


• Australia


• South Korea


• Australia


• Rest of Asia-Pacific

Rest of the World

• Middle East


• Africa


• Latin America